University of Vermont

College of Medicine

Department of Surgery

Bio for David Krag, M.D.
David Krag, M.D.

David Krag, M.D.

SD Ireland Professor of Surgery
Division of Surgical Oncology
Department of Surgery

Contact Information
Office Location:
E309C Health Sci. Complex, Surgery


M.D., Loyola Stritch School of Medicine, Maywood, IL (1980)
Internship, Yale University Medical Center, New Haven, CT  (1980-1982)
Residency in General Surgery, University of California, Davis , Sacramento, CA (1982-1986)
Fellowship in Surgical Oncology Research, John Wayne Cancer Center, Los Angeles, California (1983-1984)

Academic Appointments

SD Ireland Professorship of Surgical Oncology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT, 2000 - present
Professor of Surgery, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT, 1998 - present
Associate Professor of Surgery, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT, 1993 - 1998
Assistant Professor of Surgery, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT, 1991 - 1993
Assistant Professor of Surgery, School of Medicine, University of California, Davis, CA, 1986-1991
Assistant Professor of Surgery, School of Veterinary Medicine (Joint appointment), University of California, Davis, CA, 1987-1991

Research Grants

Title: Sentinel Node Versus Axillary Dissection: Breast Cancer (R01CA074137)
Role on Project: Principle Investigator
Funding Agency: National Institute of Health/National Cancer Institute
Funding Amount: $4,619,798
Period: 5/01/2005 - 6/30/2013

Title: Immune Analysis of Breast Cancer-Draining Lymph Nodes to Predict Clinical Outcome/ Stanford Subcontract (Peter Lee, PI)
Role on Project: Co-Investigator
Funding Agency: Stanford University Subcontract, National Institutes of Health
Funding Amount: $444,301
Period: 4/1/2007 - 3/31/2012

Awards and Honors

Endowed Chair,  SD Ireland Professorship of Surgical Oncology,  2000 - present
J. Walter Juckett Scholar Award, 2001-2003


Tehranian S, Treglia G, Krag DN, Dabbagh Kakhki VR, Zakavi SR, Sadeghi R, Keshtgar M. Sentinel node mapping in anal canal cancer: systematic review and meta-analysis. J Gastrointestin Liver Dis. 2013 Sep;22(3):321-8.

Shukla GS, Krag DN, Peletskaya EN, Pero SC, Sun YJ, Carman CL, McCahill LE, Roland TA. Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies.Cancer Immunol Immunother. 2013 Jun 5. [Epub ahead of print]

Dabbagh Kakhki VR, Bagheri R, Tehranian S, Shojaei P, Gholami H, Sadeghi R, Krag DN. Accuracy of sentinel node biopsy in esophageal carcinoma: a systematic review and meta-analysis of the pertinent literature. Surg Today. 2013 May 29. [Epub ahead of print]

Kopec JA, Colangelo LH, Land SR, Julian TB, Brown AM, Anderson SJ, Krag DN, Ashikaga T, Costatino JP, Wolmark N, Ganz PA. Relationship Between Arm Morbidity and Patient-Reported Outcomes Following Surgery in Women with Node-Negative Breast Cancer: NSABP Protocol B-32. J Support Oncol. 2013 Mar;11(1):22-30.

Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012 Sep;36(9):2239-51.

Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA. GRB7 is Required for Triple-Negative Breast Cancer Cell Invasion and Survival. Breast Cancer Res Treat. 2012;133(2):607-15.

Sun Y, Shukla G, Pero SC, Currier E, Sholler G, Krag D. Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques. 2012 Apr;0(0):1-3.

Gunzburg MJ, Ambaye ND, Del Borgo MP, Pero SC, Krag DN, Wilce MC, Wilce JA. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity. J Mol Recognit. 2012;25(1):57-67.

Ambaye ND, Pero SC, Gunzburg MJ, Yap M, Clayton DJ, Del Borgo MP, Perlmutter P, Aguilar MI, Shukla GS, Peletskaya E, Cookson MM, Krag DN, Wilce MC, Wilce JA. Structural Basis of Binding by Cyclic Nonphosphorylated Peptide Antagonists of Grb7 Implicated in Breast Cancer Progression. J Mol Biol. 2011;412(3): 397-411.

Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, Julian TB, Mamounas EP, Wolmark N. Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. N Engl J Med. 2011;364(5): 412-21.

Ambaye ND, Lim RC, Clayton DJ, Gunzburg MJ, Price JT, Pero SC, Krag DN, Wilce MC, Aguilar MI, Perlmutter P, Wilce JA. Uptake of a cell permeable G7-18NATE construct into cells and binding with the Grb7-SH2 domain. Biopolymers. 2011; 96(2): 181-8.

For more of Dr. Krag's publications, see PubMed.